Market Research Logo

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 202

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021

The global bleeding disorders treatment market is projected to reach USD 15.09 billion by 2021 from USD 10.33 billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The increasing acceptance for prophylaxis treatment among all age groups, rising volume of diagnosed patients, and increasing R&D investments for the development of hemophilia products are driving the global market for bleeding disorders treatment. On the other hand, high costs for bleeding disorder treatment products is a major factor expected to restrain the growth of this market during the forecast period.

The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products

The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.

Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
Market Penetration: Comprehensive information on the product portfolios of the top players in the bleeding disorders treatment market. The report analyses the bleeding disorders treatment market by type, drug class, and geography/ region.
Product Development/Innovation: Detailed insights on the pipeline products, R&D activities, and new product launches in the bleeding disorders treatment market.
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the bleeding disorders treatment market.
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various bleeding disorder treatment market products across geographies.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bleeding disorders treatment market.


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • STAKEHOLDERS
    • ASSUMPTIONS & LIMITATIONS
  • RESEARCH METHODOLOGY
    • RESEARCH DATA
    • SECONDARY DATA
      • KEY DATA FROM SECONDARY SOURCES
    • PRIMARY DATA
      • BREAKDOWN OF PRIMARIES
      • KEY DATA FROM PRIMARY SOURCES
      • ASSUMPTIONS
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • MARKET BREAKDOWN AND DATA TRIANGULATION
  • EXECUTIVE SUMMARY
    • INTRODUCTION
    • MARKET DYNAMICS
    • MARKET ESTIMATION
  • MARKET DYNAMICS
    • MARKET DRIVERS
    • MARKET RESTRAINTS
    • MARKET OPPORTUNITIES
    • MARKET THREATS
      • Table PIPELINE ANALYSIS (RECENTLY APPROVED)
      • Table PIPELINE ANALYSIS (TO BE APPROVED)
  • GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE
    • INTRODUCTION
      • Table GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE, 2014 2021 (USD MILLION)
    • HEMOPHILIA A
      • Table HEMOPHILIA A TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
      • Table HEMOPHILIA A TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
    • HEMOPHILIA B
      • Table HEMOPHILIA B TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
      • Table HEMOPHILIA B TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
    • VON WILLEBRAND DISEASE (vWD)
      • Table vWD TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
    • OTHERS
      • Table OTHERS TREATMENT MARKET, BY REGION, 2014 - 2021 (USD MILLION)
  • GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY DRUG CLASS
    • INTRODUCTION
      • Table GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG CLASS, 2014 2021 (USD MILLION)
    • PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET
      • Table GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
    • GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET
      • Table GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
    • GLOBAL OTHERS BLEEDING DISORDERS TREATMENT MARKET
      • Table OTHER BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY, 2014 - 2021 (USD MILLION)
  • GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY
    • INTRODUCTION
      • Table GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2014 - 2021 (USD MILLION)
      • Table NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
      • Table NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
      • Table NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
    • EUROPE
      • Table EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
      • Table EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
      • Table EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table EUROPE: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
    • ASIA-PACIFIC
      • Table ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
      • Table ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
      • Table ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
    • ROW (REST OF THE WORLD)
      • Table ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
      • Table ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
      • Table ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
      • Table ROW: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS, BY KEY PLAYERS
    • KEY GROWTH STRATEGIES, 2013 - 2016
    • KEY GROWTH STRATEGIES: NEW PRODUCT APPROVAL/ LAUNCH, 2013 - 2016
      • Table NEW PRODUCT APPROVAL/ LAUNCH, 2013 - 2016
    • KEY GROWTH STRATEGIES: AGREEMENTS, 2013 - 2016
      • Table AGREEMENTS, 2013 - 2016
    • KEY GROWTH STRATEGIES: M&A, 2013 - 2016
      • Table M&A, 2013 - 2016
    • KEY GROWTH STRATEGIES: OTHER STRATEGIES, 2013 - 2016
      • Table OTHER STRATEGIES, 2013 - 2016
  • COMPANY PROFILES
    • BAXALTA (NOW SHIRE)
      • BUSINESS OVERVIEW
      • BAXALTA (NOW SHIRE): COMPANY SNAPSHOT (PRE-ACQUISITION)
      • BAXALTA (NOW SHIRE): COMPANY SNAPSHOT (POST-ACQUISITION)
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM VIEW
    • BAYER PHARMACEUTICALS
      • BUSINESS OVERVIEW
      • BAYER PHARMACEUTICALS : COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM VIEW
    • NOVO NORDISK A/S
      • BUSINESS OVERVIEW
      • NOVO NORDISK: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM VIEW
    • PFIZER INC.
      • BUSINESS OVERVIEW
      • PFIZER: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM View
    • BIOGEN IDEC
      • BUSINESS OVERVIEW
      • BIOGEN IDEC: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM View
    • CSL BEHRING
      • BUSINESS OVERVIEW
      • CSL BEHRING: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM VIEW
    • GRIFOLS
      • BUSINESS OVERVIEW
      • GRIFOLS: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM VIEW
    • OCTAPHARMA
      • BUSINESS OVERVIEW
      • OCTAPHARMA: COMPANY SNAPSHOT
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MnM View
  • APPENDIX
    • KEY INDUSTRY INSIGHTS
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
    • RELATED REPORTS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report